Zenith Epigenetics is a biotech company developing bromodomain (BET) inhibitors for the treatment of cancer and autoimmune disorders. Zenith Epigenetics aims to become a leading epigenetic company translating bromodomain biology into impactful therapies.
Zenith Epigenetics – bromodomain inhibitors
BET (Bromodomain and ExtraTerminal domain) proteins family includes four members: BRD2, BRD3, BRD4 and BRDT. Among them, BRD4 has been associated with the regulation of some medically important genes in cancer, cardiovascular disease and autoimmune diseases. Zenith Epigenetics has a wide drug discovery platform in the area of epigenetics and develops orally active, small molecules selectively binding and inhibiting BET bromodomains. Zenith Epigenetics’ platform integrates structural biology, medicinal chemistry, modeling, biochemical and cell-based assays to discover potent compounds. These drugs are then further evaluated for desirable pharmaceutical properties in animal models of disease. Inhibition of BET bromodomain containing proteins is an exciting new epigenetic approach to treat cancer as BET inhibitors have been shown promising in preclinical tests in multiple models of hematological malignancies and solid tumors. BET inhibitors are able to repress expression of oncogenes like MYC or BCL-2, that are aberrantly highly expressed in many cancer cells. Thus, these BET inhibitors induce inhibited cell proliferation and induction of apoptotic cell death. Zenith Epigenetics’ most advanced program is a pan selective BET inhibitor being developed for hematological malignancies and solid tumors. Zenith Epigenetics’ development strategy is to focus on patient subsets with high unmet need and those that are most likely to benefit from therapy.
Zenith Epigenetic is also advancing multiple programs targeting BET bromodomains in autoimmune disease. There are 80 diseases that are believed to have an autoimmune (rheumatoid arthritis, Crohn’s disease, multiple sclerosis, Sjogren’s syndrome, psoriasis, lupus, etc…). Zenith Epigenetics discovered several different lead compounds achieving effective inhibition of BET bromodomains. These molecules are characterized by a favorable immunomodulatory profile (suppression of IL-17, TNF, IL-6 and MCP-1 production) and offer a robust efficacy in well-established in vivo animal models of multiple sclerosis and rheumatoid arthritis. Zenith Epigenetics believes that these molecules will soon provide an attractive alternative to current therapeutics.
Furthermore, drug resistance is a critical limitation across all therapeuties modalities and lots of preclinical dataset demonstrate that the treatment of these resistant cancers with BET inhibitors renders them sensitive to the various therapies. These results offer significant clinical potential for the treatment of resistant cancers with BET inhibitors.
Zenith Epigenetics’ Management Team is composed by Julie Cherrington (CEO), Sanjay Lakhotia, Brad Cann (CFO), Henrik Hansen and Ravi Jahagirdar. Board of Directors includes Peter Johann, Julie Cherrington, Kelly McNeill, Eldon Smith, Kenneth Zuerblis and Donald McCaffrey. Zenith Epigenetics carried out the spin-out of Resverlogix Corp.’s epigenetic platform technology to Zenith Epigenetics Corp. on June 2013. Zenith Epigenetics is now based in San Francisco (USA) and Calgary (Canada).
More about Zenith Epigenetics: www.zenithepigenetics.com
Zenith Epigenetics – bromodomain inhibitors – BET inhibitors – Bromodomain and ExtraTerminal domain – BET – epigenetics -Zenith – immunomodulatory – drug resistance
Zenith Epigenetics – Zenith Epigenetics Corp. – Zenith Epigenetics Corp – ZenithEpigenetics -ZenithEpigenetics.com – bromodomain inhibitor – BET inhibitor – bromodomain – BET – cancer – autoimmune disorders – autoimmune disorder – autoimmune disease – autoimmune diseases – autoimmune – BRD2 – BRD3 – BRD4 – BRDT – cardiovascular disease – drug discovery platform – drug discovery – BET bromodomains – BET bromodomain – structural biology – medicinal chemistry – modeling – biochemical – cell-based assays – MYC – BCL-2 – BCL2 – hematological malignancies – solid tumors – solid tumor – hematological – rheumatoid arthritis – Crohn’s disease – multiple sclerosis – Sjogren’s syndrome – psoriasis – lupus – Sjogren – Crohn – IL-17 – TNF – IL-6 – MCP-1 – MCP1 – IL-6 – IL17 – Julie Cherrington – Sanjay Lakhotia – Brad Cann – Henrik Hansen – Ravi Jahagirdar – Peter Johann – Kelly McNeill – Eldon Smith – Kenneth Zuerblis – Donald McCaffrey – Resverlogix Corp – Resverlogix